Veracyte
South San Francisco, California, United States · Artificial Intelligence, Biotechnology, Genetics
Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests. With a focus on genomics and clinical data, Veracyte empowers clinicians to make informed treatment decisions. Their products, especially the Decipher Prostate test, are designed to assist in assessing cancer progression risk. The company's innovative diagnostics platform
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 590
- Industries
- Artificial Intelligence, Biotechnology, Genetics
- Status
- Public (VCYT)
- Website
- veracyte.com
- Company page
Recent activity at Veracyte
- : Veracyte, Inc. acquires Convergent Genomics Inc.
- : SEC 8-K (1.01): On September 10, 2026, Veracyte, Inc. entered into a Merger Agreement with its wholly owned subsidiary, Compass Merger Sub, Inc., and Convergent Genomics Inc., along with Shareholder Representative Services LLC as the representative of securityholders. The Merger Agreement outlines the merger that took place on September 14, 2026, whereby Merger Sub merged with Convergent, resulting in Convergent becoming a wholly owned subsidiary of Veracyte. This strategic move allows Veracyte to expand its portfolio into genomic diagnostics with a focus on bladder cancer, enhancing its market offerings. The agreement signifies a critical step in Veracyte's growth strategy and integration in the biotech space.
- : SEC 8-K (2.02): On January 11, 2026, Veracyte, Inc. announced its preliminary, unaudited estimated financial results for the fourth quarter and full year ended December 31, 2025. The company expects total revenue to be between $138 million and $140 million for Q4 2025, with testing revenue between $134 million and $136 million and approximately 45,500 tests conducted. For the full year, Veracyte anticipates total revenues of between $515 million and $517 million, and testing revenues of between $491 million and $493 million, with a testing volume of around 169,700 tests, showcasing significant operational performance. The adjusted EBITDA margin is expected to exceed 25%, demonstrating robust profitability potential and strategic growth in the diagnostics sector.
- : Veracyte, Inc. launches the Decipher Prostate Test, now the only gene expression test recommended in NCCN Prostate Cancer Guidelines.
Leadership
- Boris Oklander, Chief Technology Officer
- Steven French, Chief Operating Officer
- Brent Vetter, Chief Financial Officer
- Rob Brainin, Chief Executive Officer
- Marisa H., Global Hr & People Ops Leader
- Jennifer Garcia, Hr Operations Partner
- Eron Davis, Human Resources Leader
- Bill King, Execution Based Financial Executive
- David Blevins, Finance Professional
- Luis Lazo, Vice President Finance
- Matt Halsey, Software Developer
- Paul Schock, Not Specified
Verified email and direct lines for Veracyte’s decision-makers are on Fundz. See plans
Employee benefit plans
Veracyte files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Veracyte in the news
- Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - businesswire.com (Jul 09, 2026)
- NEWSLETTER: Veracyte genomic test identifies breast cancer patients who can skip chemo - Reuters (May 27, 2026)
- Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - businesswire.com (May 22, 2026)
- Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results - Lelezard (Feb 25, 2026)
- Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - 01net (Feb 05, 2026)
- Veracyte Announces First Quarter 2026 Financial Results - businesswire.com (May 05, 2026)
- Veracyte Announces First Quarter 2025 Financial Results - BioSpace (May 08, 2025)
- Is it Worth Adding Veracyte Stock to Your Portfolio Now? - Yahoo Finance (Aug 26, 2026)
Companies similar to Veracyte
- Genoox · Artificial Intelligence, Biotechnology, Genetics, Health Care, Health Diagnostics
- Decode Health · Artificial Intelligence, Biotechnology, Genetics, Health Care, Health Diagnostics
- Breakthrough Genomics · Artificial Intelligence, Biotechnology, Genetics, Health Care, Health Diagnostics
- Gaomei Gene · Artificial Intelligence, Biotechnology, Genetics, Health Care, Health Diagnostics
- SeqOne · Artificial Intelligence, Biotechnology, Genetics, Health Care, Health Diagnostics
About Veracyte: questions and answers
What does Veracyte do?
Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests. With a focus on genomics and clinical data, Veracyte empowers clinicians to make informed treatment decisions. Their products, especially the Decipher Prostate test, are designed to assist in assessing cancer progression risk. The company's innovative diagnostics platform
Where is Veracyte headquartered?
Veracyte is headquartered in South San Francisco, California, United States.
How many employees does Veracyte have?
Veracyte has about 590 employees.
Who leads Veracyte?
Rob Brainin is a Chief Executive Officer at Veracyte.
What is the latest news on Veracyte?
On Sep 14, 2026, Veracyte, Inc. acquires Convergent Genomics Inc.
Is Veracyte a public company?
Yes. Veracyte is publicly traded under the ticker VCYT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy